Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

Some people are fair-weather friends; others are lifelong. It's a similar story with stocks. Some you might hold only ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever.The newly app ...